3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
4
Terminated
3
Recruiting
3
Active not recruiting
2
Withdrawn
1
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Melanoma
15
Carcinoma, Non-Small-Cell Lung
6
Neoplasms
4
Uveal Melanoma
3
Sarcoma
3
Prostatic Neoplasms
3
Neoplasm Metastasis
3
Pancreatic Neoplasms
2
Lung Neoplasms
2
Carcinoma, Renal Cell
2
Breast Neoplasms
2
Brain Neoplasms
2
Urogenital Neoplasms
1
Triple Negative Breast Neoplasms
1
Stomach Neoplasms
1
Squamous-Cell Lung Cancer
1
Squamous Cell Carcinoma of Head and Neck
1
Salivary Gland Neoplasms
1
Rectal Neoplasms
1
Prostatic Diseases
1
Osteosarcoma
1
Neoplastic Cells, Circulating
1
Neoplasms, Unknown Primary
1
Neoplasms by Site
1
Nasopharyngeal Carcinoma
1
Metastatic Microsatellite Stable Colorectal Cancer
1
Kidney Neoplasms
1
Hypoxia
1
Histiocytoma, Malignant Fibrous
1
Head and Neck Neoplasms
1
Interventions
Carboplatin
15
camrelizumab
11
Capecitabine
11
130-nm albumin-bound paclitaxel
10
pembrolizumab
8
eribulin
8
Paclitaxel
8
Cyclophosphamide
8
Epirubicin
7
Gemcitabine
6
Cisplatin
6
tislelizumab
5
apatinib
5
atezolizumab
4
anlotinib
4
Taxes
4
Nivolumab
4
Docetaxel
4
Bevacizumab
4
toripalimab
3
Vinorelbine
3
N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide
3
Doxorubicin
3
Albumin-Bound Paclitaxel
3
talazoparib
2
spartalizumab
2
olaparib
2
fluzoparib
2
famitinib
2
Zoledronic Acid
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Unknown
×
Triple Negative Breast Neoplasms
×
Ipilimumab
×
Clear all
NCT03818685
2024-02-12
BreastImmune03
Centre Leon Berard
Phase 2
Unknown
95 enrolled